Quick Facts

• May provide relief for symptoms of abdominal and intestinal discomfort.
• Is associated with addressing pain and spasms in the digestive tract.
• Supports management of stronger abdominal cramps, including those related to menstrual cycles.

Buscopan Composto is a therapeutic option used to address pain and cramping associated with spasms in the gastrointestinal (GI) and genitourinary tracts. The combination of its components may help relieve the discomfort and stronger abdominal cramps that arise from these spasms. This medicine is also a consideration for supporting the management of functional disorders affecting the biliary and urinary tracts, as well as the female genital organs.

The therapeutic goal of this medication is to help lessen the intensity of cramping pain and associated discomfort in these systems. This may include the use of this option for addressing the pain of stronger abdominal cramps, including those linked to menstrual cycles or colic-type conditions.

Who Can and Cannot Use Buscopan Composto?

Eligibility for Buscopan Composto, a combination of Hyoscine Butylbromide and Sodium Metamizole, is strictly defined by regulatory documents, reflecting the contraindications of both active ingredients. The following summarizes who is eligible or restricted from use.

---

Populations and Conditions for Absolute Exclusion (Contraindications)

Population / Condition	Restriction Basis
Hypersensitivity	Known allergy to Hyoscine Butylbromide, Metamizole, or other pyrazolones.
Hematological Risk	History of Metamizole-induced agranulocytosis or impaired bone marrow function.
Glaucoma / Obstruction	Narrow angle glaucoma, megacolon, or mechanical stenosis in the GI tract.
Pregnancy (3rd Trimester)	Absolute prohibition due to risk from the Metamizole component.
Infants	Contraindicated in infants below 3 months of age or 5 kg body weight.

---

Restricted and Conditional Use

Age and Development: Use is not recommended for children younger than 12 years of age. The medicine is not recommended for use in the first and second trimesters of pregnancy or while breastfeeding.

Organ Function: Patients with hepatic or renal impairment must avoid multiple high doses, as the elimination rate of the Metamizole component is reduced in these populations. Caution is also required for patients susceptible to urinary outlet obstructions or pre-existing arterial hypotension.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Buscopan Composto (Hyoscine Butylbromide and Sodium Metamizole) across pharmacodynamic and pharmacokinetic mechanisms. The profile includes specific prohibitions, required timing separation, and altered blood level risks with co-administered drugs.

Documented Interaction Patterns

Type of Interaction	Interacting Substance Categories	Official Outcome Description
Pharmacodynamic Reinforcement	Anticholinergic drugs (e.g., Antidepressants, Antipsychotics, Antihistamines)	May intensify anticholinergic effects (e.g., dry mouth, urinary retention).
	Dopamine Antagonists (e.g., Metoclopramide)	May reduce the effects of both drugs on gastrointestinal motility.
Exposure Modification	Immunosuppressants (e.g., Ciclosporin)	Metamizole may decrease the plasma concentration of the co-administered drug.
	Immunosuppressants (e.g., Methotrexate)	Increased risk for haematologic toxicity, particularly in the elderly.

Interaction-Related Restrictions and Constraints

1. Contraindicated Route: The intramuscular injection of Hyoscine Butylbromide is contraindicated in patients receiving anticoagulant drugs due to the risk of intramuscular haematoma formation.
2. Timing Requirement: Metamizole may reduce the antiplatelet effect of low-dose Aspirin used for cardioprotection; a timing separation is officially advised to mitigate this interaction.
3. Metabolic Basis: Metamizole is documented as an inducer of certain CYP enzymes (3A4, 2B6, 2C19), which can lead to lower blood levels of substrate medicines like Bupropion.

These constraints define the product's official interaction structure by identifying clinically significant additive effects and mandatory procedural limitations based on the combination and route.

Buscopan Composto operates via a synergistic dual mechanism involving peripheral spasmolysis and central antinociception. The two components target distinct molecular pathways to achieve a combined physiological effect.

Dual Visceral Smooth Muscle Relaxation

This domain covers peripheral actions that reduce smooth muscle contraction. Hyoscine butylbromide acts as an antagonist at post-ganglionic muscarinic receptors and neuronal nicotinic receptors, directly blocking the acetylcholine (ACh) signal that triggers muscle excitation. Complementary to this, metamizole provides a direct myogenic effect by influencing the release of intracellular calcium ( Ca^2+) within the muscle cell, supporting smooth muscle relaxation independent of the nerve signal. The resulting physiological effect is a dual-point spasmolysis and the inhibition of smooth muscle hyperactivity.

Attenuation of Central Pain Signaling

This domain focuses on the antinociceptive action of metamizole in the central nervous system. Its metabolites inhibit the enzyme Cyclooxygenase-3 ( COX-3), which curtails the synthesis of Prostaglandin E2 ( PGE2), a mediator that enhances central pain sensitivity. Furthermore, metamizole modulates the opioidergic and cannabinoid ( CB1) systems, engaging the body’s own descending pain control pathways. This mechanism contributes to the central attenuation of nociceptive signals.

Buscopan Composto is administered via distinct routes depending on the clinical context and the specific formulation available. The medicine is supplied for oral use as coated tablets and for parenteral administration as a solution for injection. The general pattern of use is limited to addressing acute, severe spasmodic events and is not intended for continuous, long-term administration.

For acute care needs, the parenteral route includes both intravenous (IV) and intramuscular (IM) injection. The standard adult single dose for injection is one ampoule, containing a fixed combination of 20 mg Hyoscine Butylbromide and 2.5 g Sodium Metamizole. This dose may be repeated up to two or three times within a 24-hour period, according to the dosing schedule, ensuring adequate time separation between administrations.

The IV administration has specific procedural requirements. The injection must be administered slowly, taking at least five minutes per ampoule to complete the process. Furthermore, the patient should remain in a lying position during the IV injection and immediately afterward. The IM route requires careful administration deep into the upper, outer quadrant of the buttock.

Dosage adjustments may be necessary in specific populations. For both older adult patients and those with impaired renal or hepatic function, the dosage may require reduction. The combination product is also generally excluded from use in the pediatric population under twelve months of age.

Research evidence / Overview of studies for Buscopan Composto

Research examining the Metamizole/Hyoscine Butylbromide combination was observed in study populations with acute spasmodic conditions. The evidence contributes to the broader understanding of symptom patterns in conditions characterized by fluctuating or episodic manifestations.

---

Evidence Base for Acute Visceral Colic

Research related to these conditions, which involve periods of heightened symptoms, has primarily used short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies were generally conducted in adult populations presenting to acute care settings with severe, colicky pain. Researchers monitored outcomes related to physical discomfort, primarily by using standardized scales to measure changes in pain intensity. The research base largely focuses on studies where the Metamizole component was evaluated for acute pain.

Findings describe patterns observed in the studies related to outcomes monitoring perceived discomfort. Observed outcomes were primarily short-term, with studies observing changes over defined time intervals measured within minutes or a few hours. Certainty remains low regarding the full scope of evidence, as comparative evidence is lacking to fully establish the findings related to the combination when compared to the analgesic component alone.

---

Research Landscape for Acute Abdominal Spasm and Cramping

Research exploring outcomes related to physical discomfort in conditions associated with acute or disruptive episodes includes RCTs and prospective cohort studies. These trials often used the Hyoscine Butylbromide component as a monotherapy. Research was observed in adults and certain pediatric (child) subgroups with colicky abdominal pain.

Studies report how symptoms evolved in the observed populations, sometimes describing patterns related to patient-reported outcomes describing perceived discomfort. However, some findings related to the observed outcomes of the antispasmodic component when studied alone were mixed when compared against placebo or non-opioid treatments. The available research base contains variability across studies regarding measurements of relief, and data for the specific fixed-dose combination product in this context are limited.

---

Key Limitations and Areas of Research Uncertainty

A primary limitation is that comparative evidence is lacking for the fixed-dose combination against all relevant alternative treatments across all studied indications. The research volume for the fixed-dose combination product is lower than the volume of trials available for the individual components. Subgroup findings are uncertain, meaning research is ongoing. Evidence highlights what is known—and what is still uncertain.

Key Studies & References

1. Buscopan Plus (Hyoscine Butylbromide/Acetaminophen) - DailyMed Record (Used for classification and fixed-dose combination context)

Common questions about Buscopan Composto (FAQ)

---

Q: Are there any food or drink restrictions when taking this medication?

Regulatory documents primarily detail interactions with other medicines, such as anticoagulants and immunosuppressants. While specific food or drink restrictions are not widely listed, official product information for related medicines sometimes advises against the use of alcohol during treatment. If there are specific concerns about food or drink, it is best to discuss these with a healthcare professional.

Q: How quickly can I expect Buscopan Composto to start working after I take it?

Studies and official information indicate that the time it takes to work can vary depending on the route of administration. Following an injection, the analgesic effect is typically rapid for the intravenous route and generally occurs within 20–30 minutes for the intramuscular route. For the oral tablets, a clear pain-relieving effect is generally expected within 30 to 60 minutes after taking the dose.

Q: What is the recommended dose for the oral tablets?

Official regulatory documents indicate that the dosage for the oral tablets, generally one to two tablets, is determined by a healthcare professional based on the specific condition. It is essential to follow only the directions provided on the label or by a prescriber.

Q: Is it safe to drive or operate machinery after taking Buscopan Composto?

Official regulatory documents state that treatment may cause temporary side effects such as dizziness or accommodation disorders. Accommodation disorders mean there may be difficulty focusing vision. If a patient experiences these effects, driving or operating machinery should be avoided until vision and coordination have returned to normal, as stated in the product information.

Q: What should I do if I miss a dose of the tablets?

Regulatory guidance states that if a dose is missed, the next dose should be taken when remembered, unless it is close to the time for the following dose. It is important never to take a double dose to compensate for a missed one.

Q: What does the term 'synergistic dual mechanism' mean?

This term refers to the way Buscopan Composto works, by combining two distinct actions to treat both pain and spasms. The medicine contains one component that works to relax contracted smooth muscles (antispasmodic action) and a second component that works to reduce the experience of pain (analgesic action). This combination is designed to provide a comprehensive approach to acute spasmodic pain.

Storage and Disposal Requirements

The storage and disposal of Buscopan Composto must comply strictly with official labeling to maintain product stability and safety.

Storage Conditions

Requirement	Official Condition
Maximum Temperature	Store below 25 C or 30 C (depending on the formulation).
Protection	Store in the original package, protected from light and moisture.
Child Safety	Keep out of the sight and reach of children.
Stability Limit	Do not use the medicine after the expiry date (EXP) indicated on the packaging.

Disposal Instructions

Official regulatory documents state that unused or expired Buscopan Composto must not be thrown away via wastewater or household waste. Disposal should be managed by returning the medicine to a pharmacist or following local regulated waste disposal procedures.